SCLN Share Price

Open 10.30 Change Price %
High 10.55 1 Day -0.10 -0.97
Low 10.10 1 Week 0.05 0.49
Close 10.20 1 Month 0.60 6.25
Volume 542258 1 Year 1.07 11.72
52 Week High 15.02
52 Week Low 0.00
SCLN Important Levels
Resistance 2 10.62
Resistance 1 10.45
Pivot 10.28
Support 1 9.95
Support 2 9.78
NASDAQ USA Most Active Stocks
FNFG 10.18 -0.20%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
RIMM 13.03 0.39%
BBEP 0.12 0.00%
GTAT 0.44 0.00%
SUSQ 14.20 -0.77%
ETRM 0.07 0.00%
AAPL 113.86 1.55%
AAPL 113.86 1.55%
More..
NASDAQ USA Top Gainers Stocks
HTCO 11.00 62.96%
LOCM 0.09 50.00%
OPXA 1.21 40.70%
QKLS 0.18 38.46%
ZAZA 0.08 33.33%
MOSY 0.46 31.43%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
OTT 2.39 25.13%
PPHM 0.40 25.00%
More..
NASDAQ USA Top Losers Stocks
TXCC 0.01 -95.00%
HCIIP 10.10 -67.52%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
DVOX 0.05 -44.44%
PRXI 0.21 -43.24%
TRGT 0.96 -41.46%
BGMD 0.05 -37.50%
More..

SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN)

SCLN Technical Analysis 1.5
As on 9th Dec 2016 SCLN Share Price closed @ 10.20 and we RECOMMEND Sell for LONG-TERM with Stoploss of 10.79 & Buy for SHORT-TERM with Stoploss of 9.95 we also expect STOCK to react on Following IMPORTANT LEVELS.
SCLN Target for December
1st Target up-side 11.09
2nd Target up-side 11.9
3rd Target up-side 12.7
1st Target down-side 8.81
2nd Target down-side 8
3rd Target down-side 7.2
SCLN Other Details
Segment EQ
Market Capital 307798784.00
Sector Healthcare
Industry Drug Manufacturers - Other
Offical website http://www.sciclone.com
SCLN Address
SCLN
950 Tower Lane
Suite 900
Foster City, CA 94404
United States
Phone: 650-358-3456
Fax: 650-358-3469
SCLN Latest News
Interactive Technical Analysis Chart SciClone Pharmaceuticals, Inc. ( SCLN NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on SciClone Pharmaceuticals, Inc.
SCLN Business Profile
SciClone Pharmaceuticals, Inc. (SciClone) is a specialty pharmaceutical company. The Company has a product portfolio of therapies for oncology, infectious diseases, cardiovascular, urological, respiratory and central nervous system disorders. The Company�s main product is ZADAXIN (thymalfasin), which is approved in over 30 countries, which is used for the treatment of hepatitis B virus (HBV), hepatitis C (HCV), as a vaccine adjuvant, and certain cancers. In China, thymalfasin is also included in the treatment guidelines issued by the Ministry of Health for liver cancer. SciClone�s marketed portfolio also includes Depakine, the prescribed broad-spectrum anti-convulsant in China; Tritace, an ACE inhibitor for the treatment of hypertension; Stilnox, a hypnotic for the short-term treatment of insomnia (marketed as Ambien in the United States), and Aggrastat, an intervention cardiology product. On April 18, 2011, the Company acquired NovaMed Pharmaceuticals, Inc.